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Abstract: Microparticles, microspheres, and microcapsules are widely used constituents of
multiparticulate drug delivery systems, offering both therapeutic and technological advantages.
Microparticles are generally in the 1–1000 µm size range, serve as multiunit drug delivery systems
with well-defined physiological and pharmacokinetic benefits in order to improve the effectiveness,
tolerability, and patient compliance. This paper reviews their evolution, significance, and formulation
factors (excipients and procedures), as well as their most important practical applications (inhaled
insulin, liposomal preparations). The article presents the most important structures of microparticles
(microspheres, microcapsules, coated pellets, etc.), interpreted with microscopic images too. The most
significant production processes (spray drying, extrusion, coacervation, freeze-drying, microfluidics),
the drug release mechanisms, and the commonly used excipients, the characterization, and the novel
drug delivery systems (microbubbles, microsponges), as well as the preparations used in therapy are
discussed in detail.
Keywords: multiparticulate formulations; polymer excipients; processes for microparticles in therapy;
structure and drug release; microfluidics; microbubbles; microsponge
1. Introduction
Microparticles, microspheres, and microcapsules are common constituents of multiparticulate drug
delivery systems offering numerous advantages based on their structural and functional abilities [1],
and their application is suitable for convenient and tolerable drug administration via several routes.
Depending on the formulation, they can be incorporated into different pharmaceutical dosage
forms such as solids (capsules, tablets, sachets), semisolids (gels, creams, pastes), or liquids (solutions,
suspensions, and even parenterals).
An advantage of microcarriers over nanoparticles is that they do not traverse into the interstitium
over the size of 100 nm transported by the lymph, and thus act locally [2]. Possibly toxic substances
can be carried encapsulated and liquids can be handled as solids in the form of dried microparticles.
In the case of multiparticulates, the dose is distributed in many small separate particles, which
carry and liberate a part of the dose, hence the malfunction of an individual subunit does not cause the
failure of the whole dosage.
Multiparticulate drug delivery systems offer outstanding advantages to experts and patients, such as:
- choice of dosage form for the desired drug delivery route (peroral tablets, parenteral injections);
- modified and targeted (even site-specific) drug release and delivery;
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- more expectable pharmacokinetics with reduced intra- or inter-subject variability;
- more homogenous distribution in the physiological environment;
- stable fixed-dose combinations of drugs;
- dose titration and less dose-dumping;
- patient centricity through better compliance (e.g., patients with dysphagia) and adherence;
- individual therapy (e.g., for pediatric or geriatric population);
- improving stability of the medicinal preparations;
- isolating the constituents to ensure better compatibility;
- innovative products with a prolonged life cycle through patent protection.
From the viewpoint of technology, microencapsulation provides several advantages: microparticles
are formulated in order to protect the core from the environment; masking an unpleasant taste;
preserving volatiles or the viability of the cells; separating incompatible substances; protecting the
body from the side effects; and optimizing, prolonging, or targeting the effect of a drug.
The polymer excipient protects the active pharmaceutical ingredient (API) from the environment
(oxidation, temperature, pH) or the body from the irritative, or mucosa-damaging effect of the drug
substance. The lesion (e.g., bisectioning) of the multiparticulate solid dosage form (i.e., micropellets
in spansule or compressed) affects only a small number of units, thus does not result in a significant
change of the blood level.
However, there are some limitations, such as higher product costs due to the more expensive
excipients in the formulations or to the more sophisticated equipment and processes, as well as stricter
quality control. In addition, some constituents may not meet the requirements for biocompatibility
and biodegradation.
2. Construction and Structure
Microparticles’ sizes range from 1 to 1000 µm and the well-known matrix or reservoir structure
they exist in have various different structures (Figure 1). Beyond the excipients used, the structure
and the shape determines the function as well. Multiparticulate drug delivery systems (micropellets,
microgranules, microspheres, microcapsules, microsponges, liposomal preparations) attract attention
because of their wide range of favorable technological properties.
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Figure 1. Schematic illustration of the different microparticle structures: (a) mononuclear/single
core/core-shell, (b) multi-wall, (c) polynuclear/multiple core, (d) matrix, (e) coated polynuclear core,
(f) coated matrix particle, (g) patchy microparticle, (h) dual-compartment microcapsule, (i) colloidosome,
(j) giant liposome, (k) irregular-shaped microparticle, (l) torus-shaped microparticle, (m) bullet-shaped
microparticle, (n) microtablet, and (o) cubic-shaped microparticle.
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Microparticles may be characterized as either a homogenous or heterogenous structure depending
on the formulation and processing. Usually the spheroid shape is preferred since it makes the further
processing (e.g., coating) easier.
2.1. Microspheres and Microcapsules
Microspheres can be characterized as matrix systems in which the drug is homogeneously
dispersed, either dissolved or homogenously suspended [3]. Microcapsules are heterogenous particles
where a membrane shell is surrounding the core forming a reservoir (Figure 2) [4].
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Figure 2. Structures of calcium alginate microparticles: (a) microspheres, (b) microcapsules W/O/W
emulsion in core surrounded by calcium alginate shell, and (c) “Janus particle” (the particles were
prepared by a Büchi B-390 Microencapsulator).
A classical microsphere structure contains solid or liquid API dispersed or dissolved in a matrix.
Microcapsules are reservoirs of microscopic size surrounded by a wall that is able to control the release
from the reservoir.
The size plays a role in the gastrointestinal performance: microparticles under 800 µm get
through the pylorus without the influence of gastric emptying, thus eliminating the interpersonal and
intrapersonal (nutrition-based) differences.
Particles larger than 100 nm stay at the site of administration until the phagosomal clearance.
Lymphatic uptake and node accumulation is most significant between 10–80 nm [2]. The foreign body
response is decreased by the application of spheres with a diameter of 1.5–2.5 mm compared to that of
smaller diameter spheres [5].
The surface charge has a key role in the aggregation of the particles. Aggregation hinders optimal
administration and drug delivery (e.g., compromises content uniformity of doses, occludes normal
blood flow).
Porosity also has a significance in the in vivo performance in cell transplantation. Porous materials
facilitate vascularization relative to non-porous biomaterials. A porosity of 30–40 µm leads to the
polarization of macrophages, causing elevated tissue repair [5].
Several unique anisotropic colloidal microstructures have lately been created with
special properties.
2.1.1. Janus Particles
These microparticles with a certain shape and phase anisotropy, created by alloying the distinct
properties (hydrophilic, hydrophobic) of the separated excipients, are used as multifunctional imaging
probes and sensors [6,7]. The anisotropic response to external signals has also been exploited in the
preparation of color-changing traffic signals.
2.1.2. Patchy Particles
Spherical geometries with concave, convex, or flat patches on the polystyrene sphere’s surface have
also been created via colloidal fusion and concomitant shrinking (Figure 1). The patchy particles can
form clusters, and by patch-to-patch bonding between oil patches, can build supracolloidal architectures
(tetrahedral, hexagonal) that can withstand drying forces and show the ability to reversibly expand
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several times their original volume in a swelling agent [8]. Microfluidic techniques give rise to the
creation of anisotropic geometries.
Magnetic nanoparticles embedded into nonplanar, bullet-shaped microneedles give access to mild
invasive therapy [9].
2.2. Liposomes
Liposomes are lipid vesicles with one or more phospholipid bilayers and their structure comprises
small unilamellar vesicles (SUV: 20–100 nm), large unilamellar vesicles (LUV: >100 nm), multilamellar
vesicles (MLV: >500 nm), oligolamellar (OLV: 0.1–1 µm), giant unilamellar liposomes (GUV: > 1 µm),
and multivesicular vesicles (MVV: > 1 µm).
For ophthalmic delivery, they represent ideal drug delivery systems for both hydrophilic and
hydrophobic APIs by performing a cell-membrane like structure. The negative or positive charge can
contribute to the bioavailability: cationic liposomes (e.g., fabricated with didodecyldiethylammonium
chloride, stearylamine) exhibited better efficacy at the surface of cornea with a negative charge.
Liposomes can interact with the cells via several mechanisms: interaction with the cell surface
components, fusion with the membrane, endocytosis via phagocytic cells, or swap by bilayer
components. The methods of preparation are also versatile: solvent evaporation, double
emulsion-evaporation, or reverse-phase evaporation [10].
2.3. Colloidosomes
Colloidosomes are microcapsules that contain a hollow or hydrogel core and their wall is composed
of self-assembled colloidal particles. Their sizes range from 10–20 nm to micrometers. It was found
that colloidosomes have selective permeability where drugs can diffuse through their shells via size
exclusion [11]. They can be stabilized by solid excipients (e.g., Fe2O3, CaCO3, colloidal anhydrous
silica) forming a Pickering emulsion [12]. Besides the emulsification, depending on the excipient
thermal annealing and chemical cross-linking take part in the immobilization of the active ingredient.
3. Types and Mechanism of Drug Release
The process of drug release of microparticulates, produced by special manufacturing technologies
and/or possibly containing special excipient(s), is the result of various phenomena and mechanisms
(dissolution/diffusion, osmotically driven release, erosion) (Figure 3). Generally, these mechanisms
take place side by side and one or the other mechanism provides a greater role during drug release [13].
In the microparticulate, when the active pharmaceutical ingredient is embedded in a polymer matrix
(Figure 3), the behavior of the polymer system is crucial during dissolution, but depends on many
factors (drug properties, formulation, release medium, etc.) [14].
In the case of a polymer matrix, the diffusion of the active ingredient can be through the intact
polymer network or through the pores filled with water. Water-soluble drugs may also dissolve in
the aqueous pore networks. Water uptake causes polymer chains to swell, indicating the formation
of new pores and/or osmotic pressure. During swelling, the volume increases, the effective diffusion
coefficient of the drug is increased, and more pharmacon molecules enter the aqueous part. Erosion of
the polymer matrix (bulk/surface) is also possible.
In the case of polymer coated microparticles, the film-forming polymer may dissolve in the
medium or act as a water-insoluble, permeable or semipermeable membrane. In the former case, the
diffusion is predominantly due to the release of the active ingredient. In the case of a semipermeable
coating, the osmotic phenomenon should be taken into account. It is also possible to use water-soluble
pore formers, which, by creating pores, accelerate the dissolution profile [15,16].
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In the case of smart drug delivery microparticle systems, the release of the drug occurs via a
stimulus. It is possible that one, two, or more (multiple) stimuli are required for dissolution (Figure 4).
The stimulus for drug release may be internal or external and be classified as physical, chemical, or even
microbiological. Opening and closing signals of these systems are also possible, creating feedback [17].
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for medical applications have been developed, such as magnetic resonance imaging (MRI) and drug
delivery, and they are a promising choice in tumor therapy accompanied by hyperthermia. The release
can be fine-tuned by the strength of the applied magnetic heating: with a gentle magnetic effect, the
particles react with shrinkage and slow drug release, and with intense heating, the structure disruption
induces the shrinking, which leads to a burst release [19].
Their great advantage lies in the effective method of targeting the drug molecule to the desired
site to be treated (i.e., the tumor) with higher therapeutic efficacy and lower toxicity. The reduction of
dosing frequency enhances the patient’s compliance.
The production involves emulsion methods (multiple and phase separation polymerization,
solvent extraction, hot melt microencapsulation, dispersion copolymerization).
4. Formulation and Manufacturing
4.1. Composition and Excipients
The use of plant, animal, or microbial-origin biopolymers are propitious; semi-synthetic
cellulose derivatives and biodegradable or non-biodegradable synthetic polymers are used as well.
The formulation is usually based on polysaccharides or proteins, but waxes and lipids also play a role
in the construction. Nonpolymer excipients play a role in crosslinking the polymer chains (CaCl2,
glutaraldehyde, poly-l-lysine, etc.), thus forming and hardening the polymer network of the drug
delivery systems. The most commonly used polymers and their important microencapsulation-related
properties are summarized in Tables 1–5.
Table 1. Examples of proteins and waxes of plant or animal origin used in microencapsulation.
Excipient PhysicochemicalProperties Application and Benefits Limitations Ref.
Gelatine
Amphoteric
gelatin A (isoelectric
point (IEP) pH: 7–9.4
gelatin B (IEP:
pH 4.8–5.5)
Swells, then dissolves
in water
At low pH coacervation
with negatively charged
polymers, high potential of
crosslinking
emulsifier, stabilizer (high
viscosity), binder
Thermoreversible gelling,
implantable pulmonary
delivery
pH-dependent, swelling,
dissolution, erosion
Influence of pH and
ionic strength on
behavior
Need for preservation
against possible prion
(BSE) contamination
[20,21]
Casein
Hydrophilic, metal
binding
Insoluble in water at its
IEP (pH 4.6)
calcium caseinate
–reversible thermal
gelation solubility increase
(coenzyme Q10)
Anaphylactic reactions [22]
Whey protein Insoluble at its IEP(pH 5.2)
Thermal gelation,
encapsulation of oils
film formation: gas barrier,
good tensile strength
Thermally irreversible
gel formation above
70 ◦C
Denatures at higher
salt conc.
Anaphylactic reactions
[23]
Albumin
IEP: 4.7
Freely soluble in water
negative charge at
pH 7.4
Pulmonary delivery
Alginate-albumin
Chemical degradation,
denaturation at high
salt conc.,
enzymes, heat
[24]
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Table 1. Cont.
Excipient PhysicochemicalProperties Application and Benefits Limitations Ref.
Zein
α, β, γ, δ, zein with
different Mw
amphiphilic character
IEP: 6.8
hydrophobic
Oral controlled release
matrix and wall
Brittle, rigid wall,
complex with a gelling
component to
plasticize
[25,26]
Soy protein
Partly soluble in water,
depending on the
extraction process;
IEP 4.5
Oral controlled release
matrix and wall
Emulsifier, foaming agent
Sensitivity [27]
Gluten Water-insoluble;IEP:7.5
Wall material,
good elastic, good
thermoplastic properties
Gluten sensitivity [28]
Bees-wax
(Apis mellifera)
mp (melting point):
62–64 ◦C
HLBrequired = 12
Edible, easy use, smooth
surface,
hot melt extrusion
prolonged release for
hydrophilic substances,
protection from chemical
degradation
Oxidation [29]
Carnauba wax
(Copernica
cerifera)
mp: 78–85 ◦C
HLBrequired = 12
Good compatibility
hot melt extrusion,
embedding water soluble
components, taste masking
Oxidation [30,31]
Paraffin (hard)
(mineral) mp: 50–61
◦C
Embedding water soluble
components
liquid paraffin in the
emulsification process
Sensitivity [32]
Table 2. Examples of polysaccharides of various origin used in microencapsulation.
Excipient PhysicochemicalProperties Applications and Benefits Limitations Ref.
Chitosan
(deacylated chitin)
Soluble in weak acids
Mucoadhesive
reacts with negatively
charged surfaces
Antifungal, antibacterial,
reduces LDL (low-density
lipoprotein), tissue
regenerative, pulmonary
delivery
Ionotropic gelation,
coacervation with anions,
modified emulsification
pH dependence
(insoluble above
pH 6.5)
Addition of electrolytes
precipitates chitosan in
solution,
hygroscopic
[33–35]
Sodium
hyaluronate
Anionic character,
soluble in water,
high viscosity at low
concentration
In microspheres nasal,
vaginal, ophthalmic
delivery systems
Very hygroscopic,
when heated,
emits Na2O
[36,37]
Starch
(wheat, corn,
potato, rice,
tapioca)
Starch from different
origins
Differ in particle size
and shape
Soluble in hot water
after a time of
gelatinization
Spray drying, extrusion,
molecular inclusion,
coacervation with proteins,
hydrocolloid-forming,
release via swelling,
diffusion, erosion
Hygroscopic [38]
Guar gum
Water soluble,
nonionic,
galactomannan
forms a thixotropic
solution, stable at
pH 4–10.5
Controlled-release,
colon-targeted release,
appetite suppressant,
thermoreversible
Needs preservation,
borate hinders
swelling
[39]
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Table 2. Cont.
Excipient PhysicochemicalProperties Applications and Benefits Limitations Ref.
Locust bean gum
(LBG)/carob,
ceratonia/
Nonionic,
galactomannan,
dispersible in hot
water, soluble at higher
temperature
Controlled release in
combination
pseudoplastic,
gelling with the addition
of borate, solubility not
affected by pH or ionic
concentration
Low water solubility,
hypersensitivity [40]
Konjac gum Water soluble
Elevation of temperature
increases gelation,
antioxidant properties
Indigestable [41,42]
K, ι, λ−,
Carrageenan
Anionic polymer,
ι−Carrageenan: shear
thinning thixotropic
gel forming
λ−Carrageenan: highest
anionic charge, high
solubility, but no gelling,
κ, ι−Carrageenan: elastic
gel is formed with K+,
Ca2+, thermoreversible gel
forming
Release by erosion
(physical
contact-Scentcaps®),
effective against HPV
(human papilloma virus)
Acid-catalyzed
hydrolyses, especially
at higher temperature
and pH < 3
Administration of
>2 g/kg orally Induces
intestinal ulcers, not
biodegradable
[43,44]
Agarose Soluble in hot water
swelling,
Thermoreversible gelation
(at ≈37 ◦C) with hysteresis
Poor biodegradability [45]
Sodium alginate
Water soluble, anionic
coacervation with ions
(Ca2+, Sr2+, Ba2+),
polycations (chitosan)
or poly-l-lysine
disintegrant, binder,
viscosity increasing
swelling ability (200–300×
of its own weight from
water)
pH-dependent swelling
nontoxic, nonirritant
low density (capable of
floating in gastric juice)
Diffusion, erosion,
in situ forming hydrogels
pH dependence
(insoluble in acidic
medium)
heat-sensitivity
(hydrolysis)
microbial spoilage on
storage
(depolymerization)
[46]
Tragacanth
Water soluble
arabinogalactan and
swellable bassorin
components,
swells quickly in water
Acid-resistance
emulsifier,
encapsulation of oils,
stabilizer in emulsions
Di/trivalent cations
cause drop in viscosity
because of
precipitation
[47]
Gum arabic/
Acacia gummi
(Ph. Eur.)
Water soluble, clear
solution of pH 4.5,
protective colloid
Emulsifier, spray-dry
encapsulation of flavor
and of essential oils,
30% solution has a
relatively low viscosity,
Newtonian flow
permeable coating
dietary fiber
Variation dependent
on source
pH, ionic strength
influences viscosity
(max at ≈pH 6–7)
[48–50]
Pectin
(low or high
methoxylated)
(apple, citrus peel,
beet)
Negatively charged
molecule
Gelation depends on the
degree of esterification,
cation (Ca,Zn)
concentration in solution,
temperature and pH
In situ gelling, sustained
delivery, dietary fiber,
drug delivery in colorectal
carcinoma (5-FU),
antiviral activity
Gelling occurs at low
pH (<3.5),
presence of sugars
necessary for gelation
of HM pectin
[51,52]
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Table 3. Examples of polysaccharides of microbial fermentation used in microencapsulation.
Excipient PhysicochemicalProperties Applications and Benefits Limitations Ref.
Xanthan gum
Soluble in warm and
cold water, not affected
by pH
anionic polyelectrolyte
No gelation at room temp,
cryogelation possible,
stable viscosity over wide
pH range, surface activity,
emulsion stabilizer,
controlled-release,
colon-targeted
swelling, diffusion,
matrix erosion
Hydrolysis
Acceptable daily intake
(WHO) 10 mg/kg BW
Contains cellulase
[53]
Gellan gum Anionic polyelectrolytesoluble in water
Thermoreversible gelation
with cations
sol-gel transition under
physiological conditions
bioadhesive
nasal administration
Poor biodegragability [54]
Dextran
Neutral polymer,
solubility depends on
degree of
polymerization
Colon-targeted delivery,
formation of porous
particle
pulmonary delivery
At parenteral
adiminitration:
possible platelet
adhesiveness
[55,56]
Pullulan
Neutral polymer
underivarized pullulan
has high water
solubility
Emulsifier
sustained-release
preparations
Relatively high price [57,58]
Table 4. Examples of cellulose derivatives applied in microencapsulation.
Excipient PhysicochemicalProperties Applications and Benefits Limitations Ref.
Methylcellulose
(MC)
Soluble in cold water
Tsol-gel: 80 ◦C
amphiphilic
Emulsifier, pseudoplastic
solution, pH-independent
gel formation above 50 ◦C,
high variety in Mw
Complexation with
surface-active
components,
laxative
[59]
Carboxymethyl-
cellulose sodium
(CMC-Na)
Anionic cellulose ether,
dispersible in water
(forms a colloidal
solution)
Injectable
thermoreversible
gel-forming,
mucoadhesive
Microbial instability
hygroscopicity [60,61]
Hydroxypropyl-
cellulose (HPC)
Soluble in cold water,
compatible with waxes,
oils, Tsol-gel: 55 ◦C
High surface activity
film-forming ability
Incompatible with
alkaline substances,
substituted phenol
derivatives, anionic
polymers increase
viscosity
[62]
Hydroxypropyl-
methylcellulose
(HPMC)
Water soluble,
nonionic
Reversible thermal
gelation surface activity,
emulsion stabilizer,
film-forming ability
No complex with
metallic salts or ionic
organics
[63]
Ethylcellulose Water-insoluble,hydrophobic coating
Film forming ability,
membrane-controlled
diffusion, modified release,
floating, gastroretentive
systems
Organic solvent
residuals [64]
Cellulose acetate
butyrate
Insoluble in water,
soluble in aceton-water
blends
Semipermeable coating,
extended release
formulations, diffusion,
matrix erosion
Organic solvent
residuals [65]
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Table 5. Synthetic polymers applied in microencapsulations.
Excipient PhysicochemicalProperties Applications and Benefits Limitations Ref.
Poly (lactic acid)
(PLA)
Insoluble in water
degrades to CO2 and
H2O over
12–24 months
Biodegradability,
prolonged-release in im or
sc injections, implants, oral
solid dispersions
Digestive tract
influences degradation,
parenteral
administration is
favorable, initial burst
release may occur
[64,65]
Polylactic
acid-glycolic acid
copolymer (PLGA)
Insoluble in water
lactic acid-glycolic acid
ratio influences
degradation ability to
thermoplastic gel
forming
Injectable or implantable
systems (microparticles,
gels) for human and
veterinary use,
pH- responsive/non-pH
-responsive polymer
degradation,
bone tissue engineering
Degrades into
by-products that can
induce inflammation
[66–69]
Polyacrylic acid
(Carbopol)
Neutralization with
alkaline chemicals for
gelling
Bioadhesive, targeted
delivery,
intranasal administration
with microencapsulation
Neutralization at
preparation,
preservative needed
[70]
Polymethacrylates
Soluble in organic
solvents,
most of them are
miscible with water
pH-dependent solubility,
permeability
gastric or enteric targeted
delivery possible
Water insolubility [71]
Poly-(N-
isopropylacrylamide) LCST: 35–40
◦C Thermoresponsive Not biodegradable [72,73]
Polyethylene
glycols
Liquid or solid grades
depending on the Mw,
PEG (polyethylene
glycol) 1500 freezing
point at 37–41 ◦C
Plasticizer in wall of
compressible
microcapsules,
oral insulin delivery
cell delivery in
combination
Not biodegradable [74]
Fumaryl
diketopiperazine
(FDKP)
High solubility at
pH ≥ 6,
no biological activity
Self-assembled highly
porous microparticles,
Technosphere® carrier
Not biodegradable,
excreted via urine [75]
LCST: lower critical solution temperature.
The combination of polymers of different properties is a common technique to improve the particle
characteristics and performance. Because of their opposite charges, alginate and chitosan at low pH
form a polyelectrolyte complex [76], thus decreasing the porosity of the polymer network and delay
the release of the API (Table 6).
Table 6. Synergistic polymer combinations.
Polymer Active Ingredient Particle Size PhysicochemicalMechanisms Ref
Carbohydrate-Carbohydrate
Chitosan-alginate Leydig cells 230–370 µm Complex coacervation [77]
Agarose-alginate (CaCl2) Sertoli cells 250 µm
Microfluidics ionic
gelation, [78]
Gum arabic Xylitol 100 µm doubleemulsion/coacervation [79]
Cellulose acetate butyrate
(CAB)
Sulfopropylated
dextran microspheres 40–120 µm
O/W emulsification,
solvent evaporation [65]
Gelatin + gum arabic Raspberryanthocyanins 150 µm
Emulsification,
coacervation [80]
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Table 6. Cont.
Polymer Active Ingredient Particle Size PhysicochemicalMechanisms Ref
Carbohydrate-Carbohydrate
Maltodextrin + gum arabic Lavender oil 10–20 µm S/O/W emulsification,spray-drying [50]
CMC-Na + xanthan gum Diclofenac sodium 1000–1500 µm
Emulsification, ionic
gelation,
Interpenetrating
network
[81]
LBG + PVA Buflomedilhydrochloride (BH) 350–750 µm
emulsification,
Interpenetrating
network
[40]
Chitosan + pectin Insulin 0.24–2 µm electrostaticself-assembly [82]
Carbohydrate-Protein
Gelatin + gum arabic Aspartame 100 µm
Double
emulsion/complex
coacervation
[83]
Gelatin + chitosan Citronella oil 100 µm Coacervation [33]
whey Protein +
maltodextrin Flaxseed oil ≈10 µm
emulsification, spray
drying [84]
Whey protein + alginate Flaxseed oil <10 µm
Double layer
emulsification
spray drying
[85]
Alginate + gelatin
Whey peptides
(antihypertensive
activity
1000 µm Dripping, coacervation [86]
Alginate + zein Bifidobacteriumbifidum 1200–1700 µm
Extrusion coacervation
shell-core [87]
Chitosan-zein Oral gene delivery 10 µm
Zein-sodium
tripolyphosphate
W/O emulsion
[88]
Poly-l-lysine
Poly (methyl vinyl
ether-alt-maleic
anhydride) (PMM0)
400 µm prilling, coacervation [89]
Poly (l-ornithine) +
alginate + PLA, PLGA
Superoxide dismutase,
ketoprofen 500 µm
W/O/W, O/W,
solvent evaporation [90]
Poly (l-ornithine) +
ursodeoxycholic acid,
Polystyrene sulfonate,
polyallilamine
Pancreatic ß-cells 700 µm Complex coacervation,vibrational jet [91]
Poly (ethylene glycol)
(PEG)-anthracene
alginate
Coomassie blue no data Coacervation [92]
Vinyl-sulfone terminated
PEG + alginate
Human foreskin
fibroblast 550 µm Simple coacervation [93]
Alginate +
Poly-ε-caprolactone Theophylline 800 µm Complex coacervation [94]
Polypropylene + PMMA +
ethylcellulose Verapamil 150–200 µm
O/W solvent
evaporation [95]
PLGA-alginate Rifampicin 15–50 µm Microfluidics [96]
Funami et al. [97] proved that galactomannans, including guar gum, tara gum, LBG, or konjac gum
(glucomannan), influence both the short- and long-term retrogradation process of starch by controlling
the gelation, hindering the crystallization, and improving the water-holding capacity of starch.
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Farris et al. [88] developed a peroral gene delivery system, where DNA was encapsulated in
chitosan nanoparticles and the particles were protected from the gastric environment by embedding
the nanoparticles into zein matrix microparticles with a W/O emulsification method. Zein forms a
relatively brittle film; however, alginate was successfully administered to decrease the rigidity of the
wall [87].
Several studies show that copolymerization between synthetic and natural polymers
helps to increase biocompatibility and cell viability (agarose-Carbopol®, hyaluronic
acid-polyethyleneglycol) [98]. Hydrophobic excipients (poly-ε-caprolactone) can modify the release of
low-solubility drugs from alginate by forming hydrophobic interactions with the drug molecule, thus
prolonged release can be reached [94].
Controlled-release, porous, floating microparticles were formulated by combining
polypropylene-Eudragit® RS, ethylcellulose polymers [95].
Mahou et al. successfully studied the addition of vinyl-sulfone terminated polyethyleneglycol to
alginate and thus eliminated the use of polycations for human foreskin fibroblast cell encapsulation
from a cell culture medium [93].
Wells et al. reached prolonged drug release and light-sensitive drug delivery with the chemical
modification of PEG and chemical crosslinking with alginate.
Dalpiaz et al. studied the nasal absorption of zidovudine by deoxycholic-acid-conjugated chitosan
microparticles and found that the particles could get through the blood–brain barrier, in contrast with
active efflux transporters in rats [99].
Alginate microcapsules show shrinking and lower stability in an acidic medium. κ-carrageenan
locust bean gum gel beads show lower sensitivity to acidic conditions than alginate beads. A limitation
of their use is that the formation of κ-carrageenan locust bean gum beads requires a higher
amount of potassium or calcium ions, which in terms of a healthy diet, are not acceptable in
high amounts. In cell transplantation, alginate is applied because of its excellent biocompatibility
and biodegradability. Alginate, however, has some limitations: uneven porosity, poor mechanical
strength, weak wall-formation, and easy rupture on reaction to osmotic change have been reported.
To overcome these drawbacks, excipients such as the polyelectrolytes polystyrene sulfonate (PSS)
and polyallylamine (PAA) were examined in cell microencapsulation, which improved the physical
structure of polyelectrolyte gels and complexes by reducing pore size in the microcapsule membrane.
Osmotic or mechanical stress caused lower cell leakage of these microcapsules [91]. The incorporation
of PSS and PAA were shown to attract inflammatory cells and to trigger an immune response. The same
study showed that ursodeoxycholic acid increased mechanical stability and did not affect cell viability.
Poly-l-ornithine in combination with alginate has been shown to prevent post-transplant
inflammatory response and has protected the microcapsules in vivo over the first week after
grafting [90].
As artificial cell therapy, an alginate structure strengthened by poly-l-lysine was used for
encapsulation [100]. The alkylamino groups of the polyamide chain bonds via electrostatic interactions
with alginate, thus the matrix structure has reduced porosity and good immunoprotection.
4.2. Processes for the Particle Formation
From the point of view of the industrial performance, the most important methods for
microencapsulation are the air suspension method, spray-drying, and coacervation. Figure 5
summarizes the most important techniques.
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4.2.1. Coacervation
Coacervation related to the formation of calcium alginate can be considered a classical method
for the preparation of microspheres and microcapsules. Calcium-ions form crosslinks between the
α-l-guluronic acid and β-d-mannuronic acid units of alginate, thus organizing the polymer chains into
an “eggbox-structure.” This chemical bonding gives the possibility of forming stable microspheres or
core-shell structured microcapsules (Figures 6 and 7).
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Figure 7. Images of a liquid core calcium alginate microcapsule prepared by vibration nozzle technique
(prepared by Büchi B-390 Microencapsulator) followed by coacervation: (a) oil-filled hollow particles,
(b) calcium alginate shell after removal of oil core, and (c) calcium alginate shell cut in half (average
wall thickness: 8 µm) (Images: Nikon SMZ 1000 Microscope).
Coacervation is defined as the separation of liquid phases in colloidal solutions [101]. During
coacervation, the active ingredient can be dispersed in the coating polymer solution and at a specific
environmental influence (ionic, pH, thermal change), phase separation occurs, while the core material is
encapsulated by the wall-forming polymer. Simple coacervation is based on incompatibilities between
the polymers. In most cases, it is caused by salting-out (di- or trivalent cation, as it happens with
alginate and Ca2+ or Ba2+, pectin and Ca2+). The particle size mainly depends on the excipients’
properties (viscosity, surface tension) and stirrer setup [102,103].
During complex coacervation, polyelectrolyte polymers with opposite charges form an insoluble
complex and meanwhile encapsulate the active ingredient. pH is important in complex coacervation,
as the isoelectric point of the polymers has to be taken into consideration.
Hydrophobic components are often encapsulated with coacervation. In the case of hydrophilic
components, a double emulsion process followed by a coacervation proves to be successful way to
form a core–shell structure microcapsule [79]. As a result of coacervation, the product contains a high
amount of solvent, which needs to be evaporated from the product.
For drying, besides the common processes, lyophilization (freeze-drying) offers a choice. This
is an expensive method, but effective for heat-sensitive actives. Shrinking of the particles can
be partly avoided; the end product, however, has a high porosity, which is an advantage in fast
release preparations to promote the water uptake, but is an obvious drawback in the formulation of
sustained-release preparations.
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4.2.2. Air Suspension Method/Fluid-Bed Coating
(Wurster (1959)) [104] has successfully administered fluidization in macroencapsulation for the
coating of solid particles, but it was also administered to encapsulate small particles in the size range
of 74–250 µm by Hinkes et al. [105]. The great advantage is that during the process, the particles are
suspended in an air (or inert gas) stream, in constant mixing, relative independently from each other
and the wall material solution or dispersion is sprayed on their surface, then dried inside the coating
chamber. The particle size can be tuned by the well-controllable process parameters: properties of the
core (density, hygroscopicity, surface area, particle size and shape, melting point, wettability, solubility,
volatility, compressibility, crystallinity, hardness, cohesiveness, adsorption, friability and flowability of
the core material). Concentration and quantity of wall material, inlet, outlet air temperature, and spray
settings are also critical for the process.
4.2.3. Extrusion through a Nozzle
Extrusion through a nozzle is a common method in the formation of gel particles. Many factors
influence the formation of microgels: the concentration, feeding rate, and surface tension of the
polymer solution, solvent, temperature, and nozzle diameter [3,106,107]. The solidification of the
formed microgel particles is performed in an additional step. For solidification of the gel, coacervation
(either simple or complex) is an optimal choice. The formed particles are collected in a solidification
liquid (ionic or polymer solution). The size and shape control of particles is dependent on various
factors. The distance, concentration, surface tension of the solidification liquid, and the time of the
process have a significance in the particle size and the physical properties of the beads (gel strength,
porosity, etc.). The most important limitations of the extrusion are the viscosity of the polymer because
of potential blockage of the nozzle; as such, the settings for optimal, narrow particle size distribution,
and shape are required. For the scale-up of the process, multiple-nozzle solutions have been presented.
4.2.4. Vibrational Jet/Electrostatic Extrusion
The particle formation via extrusion is completed by various processes: vibrational jet technique
means that a changing frequency vibration separates the laminar jet into beads). At the electrostatic
extrusion [108] the jet is subjected to an electric field, where having reached a certain voltage (5–6 kV),
particles are created, the repulsive forces additionally hinder their aggregation. The applied elevated
electric potential does not cause cell death [109].
4.2.5. Spinning Disk and Cutting Wire
These devices mechanically aid the particle formation and disaggregation [110].
4.2.6. Spray Drying
Spray drying is widely used in the industry for microencapsulation of volatiles, probiotics, and
viable cells. Besides the obvious drawback (high loss, low yield), the numerous advantages make this
technology very popular (uniform particle size, all steps carried out in one apparatus, use of organic
solvents, the capability of encapsulating heat-labile materials). The emulsion is sprayed into a chamber,
where warm air dries the particles, and as a result, regular shaped, micron-sized, uniform particles
are created.
The extruded wax particles can be solidified using congealing, which offers a solution for
embedding hydrophilic component to perform sustained release via the slow erosion of the wall in the
biological medium.
4.2.7. Supercritical Fluid Precipitation
This technique is capable of constructing very uniform particles, but its use is more significant in
nanoencapsulation [111].
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4.2.8. Freeze-Drying
Freeze-drying is successfully used in the microencapsulation of protein APIs. The process consists
of freezing, sublimation, primary drying, and secondary drying. At the freezing step, the eutectic point
of the components is taken into consideration. Lyoprotectants or cryoprotectants (trehalose, dextran)
can stabilize API molecules during the process by replacing water, forming a glassy matrix, reducing
molecular mobility by establishing hydrogen or van der Waals bonds between the molecules [112].
Despite its high cost, it is an advantageous process for heat-sensitive molecules.
Freeze-drying provides solidification, which then allows particles to be reconstituted in an aqueous
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Figure 8. Calcium alginate microparticles: (a) initial (prepared using a Büchi B-390 Microencapsulator),
(b) freeze-dried, and (c) reconstituted in a pH 6.8 phosphate buffer (60 min).
Table 7 summarizes the most important methods along with the parameters of the initial and final
form of microparticles.
Table 7. Classification of main procedures to prepare micropar icles, spheres, and microcapsules.
Method Typical Initial
Form of the Core
Approximate
Size (µm)
Structure
Final State
Matrix Core/Shell
Chemical
Interfacial
polymerization
In emulsion or
suspension 0.1–500 X
wet (slurry),
can be dried
In situ
polymerization
In emulsion or
suspension 1–1000 X
wet (slurry),
can be dried
Physicochemical
left In emulsion orsuspension 2–5 00 X X
wet, can be
dried
Dripping-
(Vibrating
nozzle-single;
multiple)
Droplet
formulation/extrusion;
coextrusion
10–5000 X X wet, can bedried
Solvent
evaporation
In emulsion or
suspension 0.1–5000 X X
wet, can be
dried
Spray drying
(from solution)
Droplet
formulation/spraying 1–100 X dry
Spray chilling Dropletformulation/spraying 1–100 X X dry
Fluid bed
coating/drum
coating
Solid core article 100–5000 X dry
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4.2.9. Microfluidics in Microparticle Fabrication
Microfluidics also presents promising results regarding microparticle production [113]. A wide
range of microfluidic plates have been created concerning their various structure, material, and
size [114]. Various methods are used for the engineering of microparticles such as continuous
flow-based and electrowetting-based droplet generators.
Microfluidic Droplet Generators (MFDG)
Microfluidic droplet generators (MFDG) with a T-junction, co-flowing junction, and flow-focusing
geometries are able to create, depending on the settings, monodisperse spherical or spheroid
droplets [114]. The microfluidic-based droplet generation can be implemented using active or
passive methods. In the passive method, droplets can be produced in squeezing, dripping, jetting,
tip-streaming, and tip-multibreaking modes, depending on the competition between capillary, viscous,
and inertial forces [115]. In active control, droplet generation can be manipulated by either applying
additional forces from electrical, magnetic, and centrifugal controls, or modifying intrinsic forces via
tuning fluid velocity and material properties including viscosity, interfacial tension, channel wettability,
and fluid density [115].
Coaxially assembled devices, in combination with emulsification methods, led to the production of
monodisperse microcapsules or Janus particles [116]. The polymerization occurs using a concomitant
chemical or physical reaction based on the nature of the polymer [117]. Figure 9 presents particle
formation through a PDMS (polydimethylsiloxane) hydrodynamic focusing apparatus of a W/O/W
alginate system in oil as a carrier liquid. The alginate droplets were solidified via coacervation (own
experiments).
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possibility of executing mild invasive drug delivery via microneedles. 
5. Characterization 
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Figure 9. (a) Particle generation with microfluidics with a flow-focusing-based microfluidic
droplet generator (MFDG). Particle formation was carried out with an own-developed
hydrodynamic-focusing-based microfluidic device. (b) Emulsion coacervated particle fabricated
using microfluidics.
Wu et al. [96] demonstrated that in the case of monodisperse rifampicin-PLGA core-shell
microcapsules, the burst-release can be decreased with increased encapsulation efficiency, and the
release can be controlled by increasing the wall thickness.
4.2.10. Lithography
Contact lithography was originally developed for the semiconductor industry. It is, however,
successfully applied in the replication of nonspherical particles of 500–1000 µm in size. The pattern is
transferred from a photomask to a photopolymerizable material (e.g., polyethylene-glycol- diacrylate)
using light [118]. Continuous flow lithography has better particle resolution and improved throughput.
The monomer solution is pumped through a microfluidic device, where photopolymerization occurs.
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The polymer particles (sometimes of extreme shape) are collected after having left the device [9,119] and
have been used for the controlled synthesis of bullet-shaped, 12.4-µm long, magnetic and non-magnetic
microparticles using stop-flow lithography, which gives the possibility of executing mild invasive drug
delivery via microneedles.
5. Characterization
5.1. Morphology
Size plays a crucial role in the in vivo performance of microparticles. Particles larger than 100
nm stay at the site of administration until the phagosomal clearance. Lymphatic uptake and node
accumulation is most significant between 10–80 nm [2].
5.1.1. Particle Size Analysis
Particle size analysis of microparticles above the diameter of 3 µm is in most cases carried out
based on laser light diffraction (LD) method or using a Coulter counter. In LD, the distribution indicates
the span-value, and d0.1, d0.5, and d0.9 are the parameters that can be used to compare the results.
Span-value indicates the size distribution and is calculated based on the following equation:
Span =
d0.9 − d0.1
d0.5
(1)
where 90% of the particles are under the diameter d0.9, 10% of the particles are under the diameter d0.1,
and 50% are under the diameter d0.5.
The polydispersity index (PDI) determined by dynamic laser light scattering indicates the size
distribution in the lower size region of microparticles.
5.1.2. AFM (Atomic Force Microscopy)
AFM is a technique providing information about the surface of microparticles in nanoscale by
profiling the surface [120].
5.1.3. Coulter Counter
A Coulter counter gives an absolute particle number per volume unit for various size ranges and
is very important in the particle analysis of microparticles for intravenous use [121].
5.1.4. Image Analysis
The shape determination can be more accurately achieved using microscopic (light or scanning
electron microscopy) image analysis. The shape is characterized by the roundness, aspect ratio (AR),
and the Feret-diameter. Roundness (R) is calculated using R = P
2
4piA , where P is the perimeter, and A is
the projection area. The aspect ratio is calculated using AR = DmaxDo , where Do is the longest orthogonal
diameter perpendicular to Dmax.
The aerodynamic size distribution (indicator of the particle deposition during inhalation) can be
investigated using cascade impactors (powders, aerosols, and sprays). The deposition is not solely
based on the particle size, the flow depends on the particle shape and density as well [120].
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5.2. Physicochemical Properties
Zeta-Potential Analysis
The surface charge of the particles influences physical properties (e.g., tendency to aggregation);
it also has a tremendous role in their biological performance: negatively charged surfaces
(polysaccharide-based natural molecules, e.g., polyalginic acid, hyaluronic acid, polymethacrylic acid,
etc.) attract to tissues in inflammations and are hemocompatible. Positively charged microparticles
(chitosan, Poly-l-lysine), however, present a mucoadhesive character and are non-hemocompatible [122].
Zeta potential and particle size can be determined using photon correlation spectroscopy. The
dynamic light scattering measurement is based on the Brownian movement of the particles. Zeta
potential measurements present valuable data concerning the aggregation potential of surface charged
microparticles in a suspension (above ±30 mV stable suspended particles because of repulsion), and in
indicating whether the surface-charged molecule is encapsulated or adsorbed on the surface [123].
5.3. Physical Properties
5.3.1. Density
The density of particles determines the floating capacity and concomitant disintegration or
swelling of the particle. The pycnometric method with helium gas can be used to determine this
value [124].
5.3.2. Porosity
The porosity of microparticles has a significant role in the water uptake, swelling, reconstitution,
and release mechanisms. This parameter can be measured directly using mercury porosimeters [125].
5.3.3. Microcomputed Tomography
The indirect assessment of porosity can be deducted from a microcomputed tomography assay
based on the 3D internal trabecular separation for calcium-alginate microparticles [126].
5.3.4. Flowability and Compressibility Studies
The flowability, Carr’s index, Hausner ratio, and angle of repose are significant for particles
applied in the dry state. These tests can be executed as it is described in the official pharmacopoeias
(e.g., European Pharmacopoeia, Unites States Pharmacopoeia).
5.3.5. Mechanical Test
The tensile strength and the elasticity of microparticles can be tested with a texture analyzer,
where the compression force is detected relative to the distance, and the maximum compression force
and hardness can be calculated, which indicate the mechanical resistance of the shell or the matrix
structure [124].
5.3.6. Swelling
An equilibrium swelling study can be performed to observe the behavior of dry particles under
various conditions (Figure 10). The swelling index (S%) can be calculated using the swollen particle
diameter (ds) and the initial particle diameter prior to reconstitution (di), as follows:
S(%) =
ds − di
di
× 100 (2)
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5.3.7. Wetting Property
The wetting property of the excipients can be determined using contact angle measurements [127,128].
5.4. Drug Entrapment Efficiency
The success of drug loading can be expressed by the actual loading and the entrapment
(encapsulation) efficiency:
The actual drug loading is:
DL (%) =
drug (mg)
(drug + polymer) (mg)
× 100 (3)
The general formula for calculating the entrapment efficiency value is:
EE (%) =
entrapped drug content (mg)
theoretical drug content (mg)
× 100 (4)
The ideal entrapment efficiency (100%) is influenced by various factors such as the type and
circumstances of the process [129].
5.5. Drug Release
5.5.1. In Vitro Dissolution Test for Multiparticulates
USP 42-NF 37 suggests different methods for the dissolution of multiparticulate preparations. The
apparatus and the volume are chosen based on the dosage form performance in the medium and the
volume. Compendial rotating basket (USP Apparatus 1), a reciprocating cylinder (USP Apparatus 3)
can be used for nondisintegrating coated beads, or a flow-through cell (USP Apparatus 4) can be used
for multiple dosage forms (beaded products), where sink conditions are provided.
Polymers of ionic character perform differently under various pH conditions. The independence
or dependence of drug release on the ionic strength of the medium can be proved using distinctive
pharmacopoeial methods. The medium ranges between the physiological pH 1.2–7.5 hydrochloric acid
or phosphate or acetate buffer with or without enzymes, depending on the route of administration or
the behavior of the polymer in the medium (e.g., swelling, ionization (IEP)). The use of surfactants is
possible, usually over its CMC value.
As a noncompendial apparatus, a mini-paddle-equipped small-volume apparatus, dialysis tubes,
or rotating bottle can be used.
The in vitro release mechanisms (diffusion, erosion, osmotic release, or a combination of the
previous) can be interpreted based on the models of Fick, Higuchi, Korsmeyer-Peppas, Weibull, and
Kopcha [130,131].
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5.5.2. Dissolution Test for Inhaled Particles
Inhaled particles deposit in the tracheobronchial tract depending on the size, density, and shape
of the particles. The mucus layer that provides the absorption site for drugs has a small volume
and the renewal of the absorption layer is different from that of the gastrointestinal tract; therefore,
the development of dissolution methods different from the traditional is used. USP 2, the rotating
paddle apparatus, can be used with certain modifications. The drug is set into a special cassette and an
apparatus capable of a 150 mL dissolution medium is used, agitated using mini paddles [132].
The dialysis bag method is also useable. The drug is set in the semipermeable dialysis bag,
which is immersed in the dissolution medium. The drug diffusion occurs between the two liquid
phases, and although both static and sink-conditions are maintained, the method does not simulate the
air–liquid transition.
5.5.3. In Vitro Performance of Intramuscular Injections
The in vitro dissolution study of the long-acting intramuscular injection, Risperdal® Consta®,
where the small interstitial volume provides an alternative dissolution method, was carried out in
a flow-through cell apparatus equipped with glass beads of 1 mm diameter and a pump [133]. The
in vitro dissolution data of the accelerated test, performed at a temperature above the glass transition
temperature of the polymer, correlated well with the previously published in vivo data.
In both the modified Franz diffusion cell [134] and Transwell® [135] systems, drug powder is
poured on a semipermeable membrane, which is located above the acceptor medium and diffuses
through the membrane during the test. Small volume, agitation, and regularly withdrawn samples
(sink conditions) provide the in vitro simulation of the in vivo performance.
DissolveIt® apparatus [136] presents in vitro dissolution and absorption by mimicking the in vivo
performance with a membrane separating the simulated air–blood barrier in the tracheobronchial
region of the lung and a flowing blood simulant.
5.5.4. In Vitro Dissolution Test for Topical Microsponge Preparations
A Franz diffusion cell with silastic membranes and a sink condition providing solvents
as an acceptor medium has been applied to test benzoyl-peroxid-containing microsponge gel
preparations [64].
6. Other Studies
6.1. Spectrometry
Fourier-transform infrared (FT-IR) and powder X-ray diffractometry (PXRD) analysis can be
performed to follow the intramolecular changes during microencapsulation [81]. Nuclear magnetic
resonance (NMR) studies underline the conformational changes in polymers during complexation [137].
6.2. Thermoanalytical Methods
Thermogravimetry (TG) and differential scanning calorimetry (DSC) give valuable data of the
thermal behavior of the polymer. The measurable glass transition temperature plays a significant role
in the production and the release mechanisms as well.
In the case of mucoadhesive systems, the tensile strength test, shear strength test, and the peel-off
test or in vitro wash-off test can be performed [61].
6.3. Biocompatibility
A tetrazolium-based colorimetric assay, such as an MTT (methylthiazolyldiphenyl-tetrazolium
bromide) assay, proved good to screen the cytotoxicity of hydrophylic polymers [138].
7. Applications in the Therapeutical Practice
Several types of multiparticulate sytems and product examples are detailed in Table 8 according
their type, dosage form with route of administration, drug and key excipient, and indication for use.
Sci. Pharm. 2019, 87, 20 22 of 31
Table 8. Types of multiparticulate systems in use.
Type Dosage Form Key Excipient Drug Indication Product Example
Micropellets Peroral pellets in capsule HPC Lansoprazole Proton pump inhibitor Lansoprazole®
Enteric-coated
microgranules
Delayed-release orally
disintegrating tablets Methacrylic acid, polyacrylate Lansoprazole Proton pump inhibitor Prevacid
® SoluTab™
Coated pellets Compressing pellets into anextended release tablet HPC, EC Metoprolol succinate
Cardioselective beta
blockers Betaloc
® ZOK
Microtablets Peroral minitablets in capsule Methacrylic acid-ethyl acrylate,MCC Lipase, amylase, Enzyme supply Pangrol
®
Dry powder
(Technospheres®) inhalation Fumaryl diketopiperazine Insulin Diabetes Afrezza
TM
Microspheres Im suspension injection Poly-d, l-lactid-co-glycolide Risperidone Schizophrenia Risperdal® consta
Microspheres Powder for injection Poly-d, l-lactide-co-glycolide Bromocriptine Acromegaly,parkinsonism Parlodel
® LAR
Microspheres Powder and solvent forsuspension and injection Poly-d, l-lactide-co-glycolide Octreotide
Acromegaly pancreatic
tumors Sandostatin LAR
®
Microspheres Prolonged-release suspensionfor injection Poly-d, l-lactide-co-glycolide Exenatide Diabetes type 2 Bydureon
®
Lyophilized microspheres Suspension depot injection Poly-d, l-lactid-co-glycolide Leuprolide acetate Endometriosis Lupron® depot
Liposomes Liposome inhalationsuspension
Cholesterol,
dipalmitoylphosphatidylcholine Amikacin Antibacterial Arikayce
®
Liposomes (DepoFoam™) Powder for suspension forinjection Cholesterol, DOPC, DPPG Cytarabine Neoplastic meningitis Depocyte
®
Liposomes (DepoFoam™) Powder for suspension forinjection
Cholesterol, DOPC, DPPG,
tricaprylin, triolein Morphine Epidural analgesia DepoDur
®
Microbubbles Intravenous injection Albumin Perflutren Ultrasound contrast agent Albunex®
Microbubbles Intravenous injection PEG 4000, DSPC, DPPG-Na,palmitic acid Sulfur hexafluoride Ultrasound contrast agent Lumason/SonoVue
®
Microbubbles Intravenous injection DPPA, DPPC, MPEG5000 DPPE Perflutren Ultrasound contrast agent Definity®
Microsponge Topical gel Methyl methacrylate/glycoldimethacrylate crosspolymer Tretinoin Acne vulgaris Retin A
® micro gel
Microsponge Topical cream
Methyl methacrylate glycol
dimethacrylate crosspolymer,
dimethicone.
5-fluorouracil Multiple acne/solarkeratoses Carac
® cream 0.5%
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Solid multiparticulates usually involve coated pellets or microtablets in order to ensure gastric
resistance (e.g., for acid labile proton pump inhibitor compounds) or to prolong the duration of
action and optimize the pharmacokinetic profile. Smart carrier systems react to changing pH, electric
impulse, magnetic field, and/or temperature, and have been developed in many platforms (pellets,
microgranules, microspheres).
Patient-centric medication involves the development of patient-friendly devices (e.g., DPI—Dry
Powder Inhaler) and administration routes. Inhalatives, ODTs, and nasal administration could be an
opportunity to reach a systemic effect. There is broad research on this field, however, there is only a
limited number of preparations approved by the authorities
Sustained-release injectable depot systems are capable of forming a reservoir at the site of
administration and release the API over a longer period. This property is advantageous in the
treatment of psychotic patients, or in the medication of children with acute diseases.
7.1. Insulin for Inhalation (Technosphere®)
AfrezzaTM is an immediate-release insulin formulation for Type 1 and Type 2 diabetes patients with
an optimal bioavailability (25%). The pulmonary applied preparation consists of microparticles (2–3µm)
of self-assembled fumaryl diketopiperazine (FDKP) (Mw = 452.46 Da) molecules. In this preparation,
FDKP nanocrystals are formed via a pH-induced crystallization process, and the nanocrystals are
self-assembled into a spherical microparticle, like a deck of playing cards. The front and back sides of
the “cards” provide the spheres with a high surface area, and the distance between the layers provide
the extremely high porosity, low density, and convenient aerodynamic character to deposit into the
distant alveolar regions where the API dissolves rapidly at the alveolar surfactant pH. Depending on
the API molecular weight, local (>100,000 Da) or systemic absorption is possible. Special inhalers
(Dreamboat® or Cricket®) are designed for optimal application [139].
7.2. Depocyte® (Parenteral Suspension)
Depocyte®, a liposomal product, is a pyrogen-free, parenteral suspension containing cytarabine
developed for the treatment of neoplastic meningitis (NM) via controlled release. Depocyte® is a
slow-release formulation created using DepoFoam™ technology, which includes microscopic spherical
particles (3–30 µm) and is suitable for encapsulating hydrophilic compounds in a “honeycomb-like
structure” of separated water-containing chambers. Lipid membranes separate each adjacent chamber.
Drug release is carried out over an extended time via erosion and/or reorganization of the particles’
lipid membranes. The honeycomb architecture of multivesicular DepoFoam™ particles gives allows for
a comparatively high drug loading. The injection comprising 96% aqueous foam and 4% biodegradable
lipid [140] has to be administered intrathecally every two weeks and it is metabolized by the usual
metabolic pathways for triglycerides, phospholipids, and cholesterol.
7.3. DepoDur™
Epidural morphine sulfate sustained-release liposome injection DepoDur™ is a single-dose
preparation administered at the lumbar level by the epidural route before operations. The lipid foam
contains multivesicular lipid-based particles with aqueous chambers that encapsulate the active drug.
The foam releases morphine during a 48-h period via erosion, namely the rupture of the microvesicles
(of 17–23 µm in median diameter).
7.4. Microsponge Delivery System (MDS)
Topical delivery of drugs can be achieved with microparticles of very high porosity. These
structures (of particle size of 5–300 µm) can entrap and release drugs with a controlled rate as a
response to special triggers—skin temperature change, rubbing, moisture, friction, etc.—while they
do not penetrate into the skin and perform a local effect. MDSs can achieve a very high embedding
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capacity (50–60%), and as their pore size is very small (≈0.25 µm), bacteria cannot penetrate inside, they
do not need preservatives to obtain stability. They are usually administered in the form of a gel, and the
aforementioned physical and physicochemical tests have to be accomplished with rheological studies
(viscoelasticity) [141]. The disadvantage is that by the production only organic solvent technologies
proved to be effective.
7.5. Microbubbles
Microbubbles are used as ultrasound contrasting agents, gene delivery vesicles, O2 carriers,
are thrombolytic, and facilitate the transport through the blood–brain barrier without inducing a
tissue-damaging effect [142]. Microbubble formulations contain an emulsifier, phospholipids, or protein
components, which, following sonication, entrap gases (O2, perfluorocarbons, or sulfur hexafluoride).
The product can be preserved in a lyophilized form. The maximum size may not exceed 10 µm to
avoid embolism in vivo [143].
The in vivo performance of microbubbles is influenced by the complement system of the immune
system, which is responsible for the removal of drug molecules, bacterial cells, and microbubbles
from the circulation. Studies pointed out that PEGylation reduces the immunogenicity of BSA (bovine
serum albumin) microbubbles [143].
8. Summary
In the past few decades, numerous microparticulate formulations gained therapeutical and
diagnostical significance. A great number of polymers have been tested, of which several have been
proved effective.
To accomplish the traditional coacervation, new methods have been developed (freeze-drying,
spray drying, microfluidic flow-focusing, lithography, etc.). The various created structures offer
a large potential for the fine-tuning of drug release mechanisms and the optimization of the
pharmacokinetic profile.
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